Hematopoietic SCT in Europe: data and trends in 2011

J. R. Passweg; H. Baldomero; M. Bregni; S. Cesaro; P. Dreger; R. F. Duarte; J. H. F. Falkenburg; N. Kroeger; D. Farge-Bancel; H. Bobby Gaspar; J. Marsh; M. Mohty; C. Peters; A. Sureda; A. Velardi; C. Ruiz de Elvira; A. Madrigal; European Grp Blood Marrow Transpla

doi:10.1038/bmt.2013.51

Hematopoietic SCT in Europe: data and trends in 2011

J. R. Passweg^*, H. Baldomero, M. Bregni, S. Cesaro, P. Dreger, R. F. Duarte, J. H. F. Falkenburg, N. Kroeger, D. Farge-Bancel, H. Bobby Gaspar, J. Marsh, M. Mohty, C. Peters, A. Sureda, A. Velardi, C. Ruiz de Elvira, A. Madrigal, European Grp Blood Marrow Transpla

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

109 Citations (Scopus)

Abstract

In all, 651 from 680 centers in 48 countries reported 35 660 hematopoietic SCT (HSCT) in 32 075 patients (13 470 allogeneic (42%), 18 605 autologous (58%)) to the 2011 survey. Main indications were: leukemias; 10 113 (32%; 94% allogeneic); lymphoid neoplasias; non-Hodgkin's lymphoma, Hodgkin's lymphoma, plasma cell disorders; 18 433 (57%; 12% allogeneic); solid tumours; 1573 (5%; 5% allogeneic); and non-malignant disorders; 1830 (6%; 92% allogeneic). There were more unrelated donors than HLA identical sibling donors (54% versus 39%); proportion of peripheral blood as stem cell source was 99% for autologous and 73% for allogeneic HSCT. Cord blood was only used in allogeneic transplants (6% of total). In the past 10 years, the overall number of transplants has increased by 53%. Allogeneic HSCT have doubled (from 7272 to 14 549) while, autologous have increased by 32% and continue to increase by about 1100 HSCT per year since 2001. In the past 2 years, an increase of >2000 HSCT per year was seen. Transplant activity is shown by team size. For allogeneic HSCT, we show use of reduced-intensity conditioning versus myeloablative conditioning across Europe and use of post-transplant donor lymphocyte infusions with considerable variation across different countries.

Original language	English
Pages (from-to)	1161-1167
Number of pages	7
Journal	Bone Marrow Transplantation
Volume	48
Issue number	9
DOIs	https://doi.org/10.1038/bmt.2013.51
Publication status	Published - Sept 2013

Keywords

haematopoietic SCT
reduced-intensity conditioning
transplant rates
trends
indications
STEM-CELL TRANSPLANTATION

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/bmt.2013.51

Cite this

Passweg, J. R., Baldomero, H., Bregni, M., Cesaro, S., Dreger, P., Duarte, R. F., Falkenburg, J. H. F., Kroeger, N., Farge-Bancel, D., Gaspar, H. B., Marsh, J., Mohty, M., Peters, C., Sureda, A., Velardi, A., de Elvira, C. R., Madrigal, A., & European Grp Blood Marrow Transpla (2013). Hematopoietic SCT in Europe: data and trends in 2011. Bone Marrow Transplantation, 48(9), 1161-1167. https://doi.org/10.1038/bmt.2013.51

@article{40a67fd0b4384d448dcabc4c91c44659,

title = "Hematopoietic SCT in Europe: data and trends in 2011",

abstract = "In all, 651 from 680 centers in 48 countries reported 35 660 hematopoietic SCT (HSCT) in 32 075 patients (13 470 allogeneic (42%), 18 605 autologous (58%)) to the 2011 survey. Main indications were: leukemias; 10 113 (32%; 94% allogeneic); lymphoid neoplasias; non-Hodgkin's lymphoma, Hodgkin's lymphoma, plasma cell disorders; 18 433 (57%; 12% allogeneic); solid tumours; 1573 (5%; 5% allogeneic); and non-malignant disorders; 1830 (6%; 92% allogeneic). There were more unrelated donors than HLA identical sibling donors (54% versus 39%); proportion of peripheral blood as stem cell source was 99% for autologous and 73% for allogeneic HSCT. Cord blood was only used in allogeneic transplants (6% of total). In the past 10 years, the overall number of transplants has increased by 53%. Allogeneic HSCT have doubled (from 7272 to 14 549) while, autologous have increased by 32% and continue to increase by about 1100 HSCT per year since 2001. In the past 2 years, an increase of >2000 HSCT per year was seen. Transplant activity is shown by team size. For allogeneic HSCT, we show use of reduced-intensity conditioning versus myeloablative conditioning across Europe and use of post-transplant donor lymphocyte infusions with considerable variation across different countries.",

keywords = "haematopoietic SCT, reduced-intensity conditioning, transplant rates, trends, indications, STEM-CELL TRANSPLANTATION",

author = "Passweg, {J. R.} and H. Baldomero and M. Bregni and S. Cesaro and P. Dreger and Duarte, {R. F.} and Falkenburg, {J. H. F.} and N. Kroeger and D. Farge-Bancel and Gaspar, {H. Bobby} and J. Marsh and M. Mohty and C. Peters and A. Sureda and A. Velardi and {de Elvira}, {C. Ruiz} and A. Madrigal and {European Grp Blood Marrow Transpla}",

year = "2013",

month = sep,

doi = "10.1038/bmt.2013.51",

language = "English",

volume = "48",

pages = "1161--1167",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "9",

}

Passweg, JR, Baldomero, H, Bregni, M, Cesaro, S, Dreger, P, Duarte, RF, Falkenburg, JHF, Kroeger, N, Farge-Bancel, D, Gaspar, HB, Marsh, J, Mohty, M, Peters, C, Sureda, A, Velardi, A, de Elvira, CR, Madrigal, A & European Grp Blood Marrow Transpla 2013, 'Hematopoietic SCT in Europe: data and trends in 2011', Bone Marrow Transplantation, vol. 48, no. 9, pp. 1161-1167. https://doi.org/10.1038/bmt.2013.51

TY - JOUR

T1 - Hematopoietic SCT in Europe

T2 - data and trends in 2011

AU - Passweg, J. R.

AU - Baldomero, H.

AU - Bregni, M.

AU - Cesaro, S.

AU - Dreger, P.

AU - Duarte, R. F.

AU - Falkenburg, J. H. F.

AU - Kroeger, N.

AU - Farge-Bancel, D.

AU - Gaspar, H. Bobby

AU - Marsh, J.

AU - Mohty, M.

AU - Peters, C.

AU - Sureda, A.

AU - Velardi, A.

AU - de Elvira, C. Ruiz

AU - Madrigal, A.

AU - European Grp Blood Marrow Transpla

PY - 2013/9

Y1 - 2013/9

N2 - In all, 651 from 680 centers in 48 countries reported 35 660 hematopoietic SCT (HSCT) in 32 075 patients (13 470 allogeneic (42%), 18 605 autologous (58%)) to the 2011 survey. Main indications were: leukemias; 10 113 (32%; 94% allogeneic); lymphoid neoplasias; non-Hodgkin's lymphoma, Hodgkin's lymphoma, plasma cell disorders; 18 433 (57%; 12% allogeneic); solid tumours; 1573 (5%; 5% allogeneic); and non-malignant disorders; 1830 (6%; 92% allogeneic). There were more unrelated donors than HLA identical sibling donors (54% versus 39%); proportion of peripheral blood as stem cell source was 99% for autologous and 73% for allogeneic HSCT. Cord blood was only used in allogeneic transplants (6% of total). In the past 10 years, the overall number of transplants has increased by 53%. Allogeneic HSCT have doubled (from 7272 to 14 549) while, autologous have increased by 32% and continue to increase by about 1100 HSCT per year since 2001. In the past 2 years, an increase of >2000 HSCT per year was seen. Transplant activity is shown by team size. For allogeneic HSCT, we show use of reduced-intensity conditioning versus myeloablative conditioning across Europe and use of post-transplant donor lymphocyte infusions with considerable variation across different countries.

AB - In all, 651 from 680 centers in 48 countries reported 35 660 hematopoietic SCT (HSCT) in 32 075 patients (13 470 allogeneic (42%), 18 605 autologous (58%)) to the 2011 survey. Main indications were: leukemias; 10 113 (32%; 94% allogeneic); lymphoid neoplasias; non-Hodgkin's lymphoma, Hodgkin's lymphoma, plasma cell disorders; 18 433 (57%; 12% allogeneic); solid tumours; 1573 (5%; 5% allogeneic); and non-malignant disorders; 1830 (6%; 92% allogeneic). There were more unrelated donors than HLA identical sibling donors (54% versus 39%); proportion of peripheral blood as stem cell source was 99% for autologous and 73% for allogeneic HSCT. Cord blood was only used in allogeneic transplants (6% of total). In the past 10 years, the overall number of transplants has increased by 53%. Allogeneic HSCT have doubled (from 7272 to 14 549) while, autologous have increased by 32% and continue to increase by about 1100 HSCT per year since 2001. In the past 2 years, an increase of >2000 HSCT per year was seen. Transplant activity is shown by team size. For allogeneic HSCT, we show use of reduced-intensity conditioning versus myeloablative conditioning across Europe and use of post-transplant donor lymphocyte infusions with considerable variation across different countries.

KW - haematopoietic SCT

KW - reduced-intensity conditioning

KW - transplant rates

KW - trends

KW - indications

KW - STEM-CELL TRANSPLANTATION

U2 - 10.1038/bmt.2013.51

DO - 10.1038/bmt.2013.51

M3 - Article

SN - 0268-3369

VL - 48

SP - 1161

EP - 1167

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

IS - 9

ER -

Hematopoietic SCT in Europe: data and trends in 2011

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this